-
Product Insights
Encephalitis - Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Encephalitis - Global Clinical Trials Review, 2025" provides an overview of Encephalitis Clinical trials scenario. This report provides top line data relating to the clinical trials on Encephalitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Bronchiectasis - Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Bronchiectasis - Global Clinical Trials Review, 2025" provides an overview of Bronchiectasis Clinical trials scenario. This report provides top line data relating to the clinical trials on Bronchiectasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Gastroenteritis - Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Gastroenteritis - Global Clinical Trials Review, 2025" provides an overview of Gastroenteritis Clinical trials scenario. This report provides top line data relating to the clinical trials on Gastroenteritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Systemic Lupus Erythematosus and Lupus Nephritis: Epidemiology Forecast to 2034
Systemic lupus erythematosus (SLE) is the most common form of lupus. It is an autoimmune disease in which the body’s immune system mistakenly attacks its own healthy cells and organs, leading to inflammation and damage (Centers for Disease Control and Prevention, 2024). SLE is a chronic disease that can affect the skin, joints, blood, and organs such as the kidneys, lungs, and heart. There is currently no cure for SLE, but it can be treated. LN is one of the...
-
Sector Analysis
Age-Related Macular Degeneration Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
The table below presents the key metrics for age-related macular degeneration (AMD) in the seven major pharmaceutical markets (7MM) covered in this report—the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan—during the forecast period from 2024–34. In 2024, GlobalData estimated the total AMD market to be valued at $7.8 billion across the 7MM, with the US accounting for 67.2% of the market. The five major European markets (5EU) (France, Germany, Italy, Spain, and UK) accounted for 28.9%...
-
Sector Analysis
Age-Related Macular Degeneration: 68-Market Analysis and Sales Forecast tp 2034
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Age-Related Macular Degeneration (AMD) market. Across the 68 markets, sales in the AMD market were $8.9 billion in 2024, growing to $24.1 billion in 2034. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 87.0% and 85.2% in 68-market sales in 2024 and 2034, respectively.
-
Sector Analysis
Evaluating the Trump Administration’s New MFN Medicaid GENEROUS Model
Since the US president Donald Trump issued the Most Favored Nation (MFN) executive order, several pharmaceutical companies have agreed to comply with MFN pricing and more are expected to fall in line in the future. The Trump administration also recently revealed a new program for Medicaid, dubbed the GENErating cost Reductions fOr U.S. Medicaid (GENEROUS) model, where State Medicaid programs will be able to purchase drugs at MFN prices. The GENEROUS model revealed details on how international reference pricing (IRP)...
-
Sector Analysis
Resistant Hypertension: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2034
Understand the Future of the Resistant Hypertension Market The resistant hypertension (RH) therapeutics market is entering a new phase of growth as unmet medical needs, evolving treatment strategies, and pipeline innovation reshape the competitive landscape. This report provides a detailed analysis of the RH market across the 7MM (US, 5EU, and Japan), supported by an Excel-based forecast model through 2034. The report highlights a projected increase in diagnosed prevalent cases of resistant hypertension across the forecast period, alongside growing demand...
-
Thematic Analysis
FDI Trends in LATAM (2025)
Foreign Direct Investment (FDI) in the Latin American (LATAM) region is projected to increase in 2025, sculpted by commodity demand, competing US-Chinese investments, and expanded bilateral trade agreements conductive of FDI inflows. According to GlobalData’s FDI database, opened Greenfield FDI projects are projected to increase by ~1.8% in 2025, preceding consecutive years of growth in 2022, 2023 and 2024. Bucking the global trend, Foreign Direct Investment (FDI) in the Latin American (LATAM) region is projected to increase in 2025, sculpted...
-
Sector Analysis
Idiopathic Pulmonary Fibrosis (IPF) Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 7 major markets and provides an Excel-based forecast model for the Idiopathic Pulmonary Fibrosis (IPF) market through 2034. GlobalData estimated that drug sales for IPF in 2024 were approximately $2.7 billion across the 7MM, with the market size anticipated to grow to approximately $5.8 billion by 2034, at a compound annual growth rate (CAGR) of 7.7%. Major drivers of growth during the forecast period include the launches of several pipeline agents, most notably Jascayd (nerandomilast), Tyvaso...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.